Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia

Saran Vardhanabhuti; Babafemi Taiwo; Daniel R. Kuritzkes; Joseph J. Eron; Ronald J. Bosch

doi:10.3851/IMP2772

Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia

Saran Vardhanabhuti^*, Babafemi Taiwo, Daniel R. Kuritzkes, Joseph J. Eron, Ronald J. Bosch

^*Corresponding author for this work

Medicine, Infectious Diseases Division

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Background: Persistent low-level viraemia (LLV) during the treatment of antiretroviral therapy (ART) is associated with emergent drug resistance mutation (DRM); however, insight into its driver is limited. The objectives were to study HIV-1 pol sequence evolution in subjects with persistent LLV and evaluate factors associated with sequence changes. Methods: HIV-1 pol sequences from 54 treatment-naive subjects undergoing first-line lopinavir/ritonavir- or efavirenz-containing ART were obtained at pre-ART and end of LLV. HIV-1 sequence evolution was evaluated using phylogenetic analysis and Hamming distance calculation. DRMs were interpreted based on the International AIDS Society-USA 2011 update.

Original language	English (US)
Pages (from-to)	73-76
Number of pages	4
Journal	Antiviral Therapy
Volume	20
Issue number	1
DOIs	https://doi.org/10.3851/IMP2772
State	Published - 2015

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3851/IMP2772

Cite this

@article{0586de1596fd4b61866cd2664c6d768e,

title = "Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia",

abstract = "Background: Persistent low-level viraemia (LLV) during the treatment of antiretroviral therapy (ART) is associated with emergent drug resistance mutation (DRM); however, insight into its driver is limited. The objectives were to study HIV-1 pol sequence evolution in subjects with persistent LLV and evaluate factors associated with sequence changes. Methods: HIV-1 pol sequences from 54 treatment-naive subjects undergoing first-line lopinavir/ritonavir- or efavirenz-containing ART were obtained at pre-ART and end of LLV. HIV-1 sequence evolution was evaluated using phylogenetic analysis and Hamming distance calculation. DRMs were interpreted based on the International AIDS Society-USA 2011 update.",

author = "Saran Vardhanabhuti and Babafemi Taiwo and Kuritzkes, {Daniel R.} and Eron, {Joseph J.} and Bosch, {Ronald J.}",

note = "Publisher Copyright: {\textcopyright} 2015 International Medical Press.",

year = "2015",

doi = "10.3851/IMP2772",

language = "English (US)",

volume = "20",

pages = "73--76",

journal = "Antiviral Therapy",

issn = "1359-6535",

publisher = "Sage Publications",

number = "1",

}

TY - JOUR

T1 - Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia

AU - Vardhanabhuti, Saran

AU - Taiwo, Babafemi

AU - Kuritzkes, Daniel R.

AU - Eron, Joseph J.

AU - Bosch, Ronald J.

PY - 2015

Y1 - 2015

N2 - Background: Persistent low-level viraemia (LLV) during the treatment of antiretroviral therapy (ART) is associated with emergent drug resistance mutation (DRM); however, insight into its driver is limited. The objectives were to study HIV-1 pol sequence evolution in subjects with persistent LLV and evaluate factors associated with sequence changes. Methods: HIV-1 pol sequences from 54 treatment-naive subjects undergoing first-line lopinavir/ritonavir- or efavirenz-containing ART were obtained at pre-ART and end of LLV. HIV-1 sequence evolution was evaluated using phylogenetic analysis and Hamming distance calculation. DRMs were interpreted based on the International AIDS Society-USA 2011 update.

AB - Background: Persistent low-level viraemia (LLV) during the treatment of antiretroviral therapy (ART) is associated with emergent drug resistance mutation (DRM); however, insight into its driver is limited. The objectives were to study HIV-1 pol sequence evolution in subjects with persistent LLV and evaluate factors associated with sequence changes. Methods: HIV-1 pol sequences from 54 treatment-naive subjects undergoing first-line lopinavir/ritonavir- or efavirenz-containing ART were obtained at pre-ART and end of LLV. HIV-1 sequence evolution was evaluated using phylogenetic analysis and Hamming distance calculation. DRMs were interpreted based on the International AIDS Society-USA 2011 update.

UR - http://www.scopus.com/inward/record.url?scp=84927945215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927945215&partnerID=8YFLogxK

U2 - 10.3851/IMP2772

DO - 10.3851/IMP2772

M3 - Article

C2 - 24699164

AN - SCOPUS:84927945215

SN - 1359-6535

VL - 20

SP - 73

EP - 76

JO - Antiviral Therapy

JF - Antiviral Therapy

IS - 1

ER -

Phylogenetic evidence of HIV-1 sequence evolution in subjects with persistent low-level viraemia

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this